welcome to cyprotex
home > contact

Contact Us

 
Customer Service & Quote Requests

request

 

Department Directory

 

Address

 
United Kingdom (Headquarters)
15 Beech Lane,
Macclesfield,
Cheshire
SK10 2DR
United Kingdom
 
Tel: +44 (0)1625 505100
Fax: +44 (0)1625 505199
 
United States
313 Pleasant St.,
Watertown,
MA 02472
USA
 
 
Tel: +1-888-297-7683
Fax: +1-617-812-0712
 
Map & driving directions
 
 
Advertising, Trade Shows, Sponsorships, Marketing
Katya Tsaioun
Tel: +44 625 505100
Email: marketing@cyprotex.com
 
Finance
John Dootson
Tel: +44 625 505100
Email: j.dootson@cyprotex.com
 
Human Resources
Mark Warburton
Tel: +44 1625 505117
Email: m.warburton@cyprotex.com
 
Investor Relations
Anthony Baxter/Mark Warburton
Tel: +44 1625 505100
Email: ir@cyprotex.com
 
Product Development
Helen Gill
Tel: +44 1625 505115
Email: h.gill@cyprotex.com
 
All Other Inquiries
T: +44 1625 505100
F: +44 1625 505199
request
Tell us what services you're interested in and we'll send you a quote.
request
spotlight on

Genomic ADME - gADME™

Cyprotex's proprietary gADME™ system can alert you to genetic variations in drug metabolism, allowing for personalised doses, drug rescue and repositioning.
Learn more about gADME

In vitro Micronucleus Test

Cyprotex now offers the in vitro micronucleus test for genotoxicity assessment using an automated, high content screening method for improved detection and reliability.
Learn more about our in vitro MNT service

Drug Transporters

Cyprotex provides a full range of drug-transporter studies as recommended by the ITC white paper and EMA guidelines.
Learn more about transporters

ADMET for Medicinal Chemists: A Practical Guide
ADMET for Medicinal Chemists: A Practical Guide
By Dr. Katya Tsaioun, Chief Scientific Officer, Cyprotex
Wiley & Sons, March 2011
Save 20%! Request your discount coupon.
request
careerscontactlegalprivacy
This website was last updated
on 3rd February 2012
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.